Item 5.07Item 5.07 - Submission of Matters to Vote
Item Submission
5.07 of Matters to a Vote of Security Holders.
At
the Annual Meeting of stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), held
on September 28, 2026, the Company’s stockholders voted on the matters described below. The number of shares of common stock entitled
to vote at the Annual Meeting was 2,011,057. The number of shares of common stock present or represented by proxy at the Annual Meeting
was 951,746. The voting results for the proposals are as follows:
Proposal
1. The Company’s stockholders elected the following four director nominees to serve until the date of the next Annual Meeting
of stockholders following the date such persons are elected as directors, and until their successors are duly elected and qualified.
The results of the vote are summarized in the table below.
Director Votes Votes Broker
Nominees For Withheld Non-Votes
──────────────────────────────────────────────────────
Bruce 152,615 3,941 758,866
Stroever
Siddhesh 155,570 3,842 758,866
Angle
Robert 158,799 3,892 758,866
Gagnon
Philip 158,783 3,891 758,866
Meikle
Proposal
2. The Company’s stockholders approved, on an advisory basis, the Company’s executive compensation. The results of
the vote are summarized in the table below.
Votes Votes Abstentions Broker
For Against Non-Votes
────────────────────────────────────────────────────────
139,592 49,851 3,437 758,866
Proposal
3. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote are summarized in the table
below.
Votes Votes Abstentions
For Against
─────────────────────────────────────────
898,011 49,834 3,901
Proposal
4. The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance
of shares of the Company’s common stock underlying certain warrants issued by us pursuant to that certain Securities Purchase Agreement,
dated as of July 7, 2026, by and among the Company and the investor named on the signatory pages thereto, and that certain Engagement
Letter, by and among the Company and H.C. Wainwright & Co., LLC, dated as of March 11, 2025, as amended, in an amount equal to or
in excess of 20% of the Company’s common stock outstanding immediately prior to the issuance of such warrants. The results of the
vote are summarized in the table below.
Votes Votes Abstentions Broker
For Against Non-Votes
────────────────────────────────────────────────────────
147,340 42,233 3,307 758,866
Proposal
5. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation,
as amended, to effect a reverse stock split of its outstanding common stock in a range of not less than 1-for-2 but not more than 1-for-10,
at the discretion of the board of directors. The results of the vote are summarized in the table below.
Votes Votes Abstentions
For Against
─────────────────────────────────────────
806,603 137,720 7,423
Proposal
6. The Company’s stockholders approved a proposal to adjourn the Annual Meeting, if necessary or appropriate, if there are
not sufficient votes at the time of the Annual Meeting to approve the proposals submitted to the Company’s stockholders and/or
establish a quorum for the Annual Meeting. The results of the vote are summarized in the table below.
Votes Votes Abstentions
For Against
─────────────────────────────────────────
806,477 137,919 7,350
Broker
non-votes represent shares held by broker nominees for beneficial owners that were not voted because the broker nominee did not receive
voting instructions from the beneficial owner and lacked discretionary authority to vote the shares on a non-routine proposal.
Because
Proposals 1, 2, 3, 4 and 5 were approved by the Company’s stockholders, an adjournment of the Annual Meeting was not necessary.